GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion. Wide-moat GSK’s third-quarter earnings aligned with our ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

and robust product delivery practices, including building supply capacity. The drugmaker's chief executive, Emma Walmsley noted this is the eighth time that GSK had headed the list, and comes ...

Another big name in the pharmaceutical and vaccine space, GSK rejoins our list of best stocks to buy now. The firm’s innovative new product lineup and expansive list of patent-protected drugs ...

The Nigerian economy has seen the closure of many companies, especially multinational firms, which threw many Nigerians into ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Q3 2024 Earnings Call Transcript October 30, 2024 GSK plc beats earnings expectations. Reported EPS is $1.29, expectations were $1.23. Operator: Hello, everyone. Welcome to today’s call and webcast.

Given the lack of innovation and over-reliance on existing products, I recommend a "sell" rating for Haleon, questioning its standalone success and justification for current valuation. GSK chose ...